Related Experiment Video
Updated: Sep 2, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Effect of kidney function on drug concentrations of first-line anti-tubercular treatment
Divya Datta1, Indu Ramachandra Rao1, Raghavendra Shetty2
1Department of Nephrology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
Background:
Tuberculosis (TB) and chronic kidney disease (CKD) are interconnected global health concerns. CKD patients have a higher risk of developing TB. Decreased clearance of drugs in kidney disease enhances toxicity risk. Current guidance on medication doses is not based on therapeutic drug monitoring. We measured and compared the concentrations of first-line anti-TB drugs in CKD and those with normal kidney function.
Methods:
A prospective observational study was conducted from September 2020 to December 2023. Patients with microbiologically confirmed tuberculosis were included, and drug concentrations were determined by using Liquid Chromatography-Tandem Mass Spectrometer (LC-MS/MS) and compared between CKD and those with normal kidney function.
Results:
Of 151 participants, 51 had CKD. Higher trough concentrations were found in CKD for isoniazid [697.15 ng/mL (IQR 199.07-3321.68) vs. 187.58 ng/mL (IQR 95.56-323.65), P < 0.0001], rifampicin [141.53 ng/mL (IQR 40.86-730.66) vs. 33.24 ng/mL (IQR 22.49-86.20), P < 0.0001], and ethambutol [635.67 ng/mL (IQR 264.38-1594.12) vs. 230.92 ng/mL (IQR 161.95-417.22), P < 0.0001], while pyrazinamide level [1469.79 ng/mL (IQR 0.00-5160.53) vs. 4273.94 ng/mL (IQR 2151.29-8023.81), P = 0.002] was higher in those with normal kidney function. At 2-hours, a greater number of CKD patients had below the reference threshold for rifampicin [33/51 (64.7%) vs. 48/100 (48%), P = 0.059] and pyrazinamide [39/40 (97.5%) vs. 29/91 (31.8%), P < 0.0001].
Conclusion:
CKD affects anti-tubercular drug concentrations, highlighting the need for therapeutic drug monitoring.
Clinical Trial Registration Number:
CTRI/2020/09/027951.
Related Concept Videos
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Renal Drug Excretion: Tubular Reabsorption
Drug Elimination by Renal Route: Tubular Secretion
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted less...
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
Renal Drug Excretion: Tubular Secretion